Blackstone Bets On Pharma In First Japan Buy, But Why?
Executive Summary
Major private equity group Blackstone buys into pharma for its first acquisition in Japan, but amid challenges in the sector, the attractions take some unraveling.
You may also be interested in...
Blackstone Emerges As Likely Buyer For Takeda's OTC Business At Price Close To $3Bn
Takeda's divestment long has been rumored and would take it to its oft-stated target of selling around $10bn in assets to pay down debt associated with its $62bn purchase of Shire that closed in January 2019.
Ferring And Blackstone Launch Gene Therapy Company
The Swiss group has decided to launch FerGene with the private equity giant to give the gene therapy nadofaragene firadenovec, which has a priority review at the FDA, a better chance for a successful launch in the US.
Lupin Offloads Kyowa For $525m But Not Exiting Japan
Lupin plans to invest in acquisitions and organic growth in the US and India after selling Japanese subsidiary Kyowa Pharma for an enterprise value of around $525m to Japan private equity group Unison Capital. But the Indian firm stresses it is not exiting Japan and will continue to look for marketing partnerships.